BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
November 19, 2021 06:30 ET
|
BioNTech SE
MAINZ, GERMANY, November 19, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111,...
Pfizer und BioNTech beliefern U.S.-Regierung mit 50 Millionen weiteren Kinderimpfdosen des COVID-19-Impfstoffs zur Vorbereitung auf zukünftigen Bedarf
October 28, 2021 06:58 ET
|
BioNTech SE
Impfdosen werden vermutlich bis April 2022 geliefert NEW YORK und MAINZ, Deutschland, 28. Oktober 2021 — Pfizer Inc. (NYSE: PFE, “Pfizer”) und BioNTech SE (Nasdaq: BNTX, “BioNTech”) gaben heute...
Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
October 28, 2021 06:58 ET
|
BioNTech SE
Doses expected to be delivered by April 2022 NEW YORK and MAINZ, GERMANY, October 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has...
BioNTech plant Mitte 2022 den Baubeginn einer mRNA Impfstoff-Produktionsstätte in Afrika
October 26, 2021 08:00 ET
|
BioNTech SE
BioNTech unterzeichnet eine Absichtserklärung mit der ruandischen Regierung und dem Institut Pasteur de Dakar. Der Baubeginn für die erste mRNA-Produktionsstätte in Afrika ist für Mitte 2022...
BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022
October 26, 2021 08:00 ET
|
BioNTech SE
BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Construction of the first mRNA manufacturing facility in Africa is planned to be initiated in...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
June 22, 2021 01:00 ET
|
Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program
June 07, 2021 07:30 ET
|
Translate Bio, Inc.
-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to...
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
April 19, 2021 07:30 ET
|
Translate Bio, Inc.
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy...
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
March 12, 2021 01:00 ET
|
Translate Bio, Inc.
-- Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels -- -- Expected to enroll 415 participants; interim results...
Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress
February 25, 2021 16:05 ET
|
Translate Bio, Inc.
-- Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) -- -- Two infectious disease mRNA vaccine programs expected to enter...